**Question:** Best Hormonal contraceptive for sickle cell anemia patient is

A. Depot medroxyprogesterone acetate (DMPA)
B. Levonorgestrel-releasing intrauterine device (LNG-IUD)
C. Medroxyprogesterone acetate (MPA)
D. Ethinyl estradiol and norethindrone (EE/NET) combination

**Correct Answer:** .

**Core Concept:** Sickle cell anemia is a genetic disorder causing hemolytic anemia due to abnormal hemoglobin variants. Hormonal contraceptives are commonly used as a safe and effective method of contraception. The choice of contraceptive in a sickle cell anemia patient depends on several factors, including patient preference, potential side effects, and risk of complications.

**Why the Correct Answer is Right:** The correct hormonal contraceptive option for a sickle cell anemia patient is Levonorgestrel-releasing intrauterine device (LNG-IUD). The LNG-IUD releases levonorgestrel, a progestin hormone, directly into the uterine cavity, providing contraception without affecting systemic hormonal levels. This choice is preferred because it does not involve systemic hormonal levels, reducing the risk of exacerbating hemolysis in sickle cell anemia patients.

**Why Each Wrong Option is Incorrect:**

A. Depot medroxyprogesterone acetate (DMPA): DMPA is a long-acting injectable progestin steroid that causes significant suppression of the hypothalamic-pituitary-ovarian axis, leading to a higher risk of exacerbating hemolysis in sickle cell anemia patients.

B. Levonorgestrel-releasing intrauterine device (LNG-IUD): LNG-IUD is a safe option, as explained above.

C. Medroxyprogesterone acetate (MPA): MPA is a long-acting progestin steroid, which could potentially exacerbate hemolysis in sickle cell anemia patients.

D. Ethinyl estradiol and norethindrone (EE/NET) combination: EE/NET is a combination of ethinyl estradiol (estrogen) and norethindrone (progestin), which could potentially exacerbate hemolysis in sickle cell anemia patients.

**Clinical Pearl:** In sickle cell anemia patients, the use of hormonal contraceptives should be carefully considered, weighing the potential risks and benefits. In most cases, the LNG-IUD is the preferred option due to its local action without affecting systemic hormonal levels, reducing the risk of exacerbating hemolysis. Always consult with the patient, discuss the risks and benefits, and obtain informed consent before prescribing any hormonal contraceptive to a sickle cell anemia patient.